Last reviewed · How we verify

Discontinuation of Azathioprin — Competitive Intelligence Brief

Discontinuation of Azathioprin (Discontinuation of Azathioprin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Discontinuation of Azathioprin (Discontinuation of Azathioprin) — University of Zurich. Discontinuation of azathioprine involves the cessation of an immunosuppressive drug that inhibits purine synthesis, thereby reducing the suppression of T and B lymphocyte proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Discontinuation of Azathioprin TARGET Discontinuation of Azathioprin University of Zurich marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Discontinuation of Azathioprin — Competitive Intelligence Brief. https://druglandscape.com/ci/discontinuation-of-azathioprin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: